| Literature DB >> 29588731 |
Maurizio Taramasso1, Christelle Calen1, Andrea Guidotti1, Shingo Kuwata1, Hector Rodriguez Cetina Biefer1, Fabian Nietlispach1, Michel Zuber1, Francesco Maisano1.
Abstract
Surgical treatment is the gold standard treatment of functional tricuspid regurgitation (FTR) but this carries high risks of morbidity and mortality. Percutaneous procedures are an attractive alternative to surgery for selected patients deemed to be high-risk surgical candidates. A number of tricuspid transcatheter devices have been developed to treat FTR, but at present, evidence of their efficacy and safety is scarce. Preliminary data have shown promising results, but ongoing and future studies will provide a clearer picture of the benefits of these new techniques.Entities:
Keywords: Tricuspid regurgitation; annuloplasty; transcatheter; tricuspid valve spacer
Year: 2017 PMID: 29588731 PMCID: PMC5808466 DOI: 10.15420/icr.2017:3:2
Source DB: PubMed Journal: Interv Cardiol ISSN: 1756-1485